The Genetics of Parkinson’s Disease

1. The Genetic Architecture of PD

Parkinson’s disease was viewed as a paradigmatic sporadic disease until the mid-1990s. It is now understood as a complex genetic disorder in which:

• ~5–10% of cases are monogenic, with mutations in known PD genes (SNCA, LRRK2, PRKN, PINK1, DJ-1, VPS35, GBA biallelic).
• ~25% of cases carry at least one strong risk allele — most prominently a heterozygous GBA variant or LRRK2 G2019S.
• ~22% of disease liability is captured by ~90 loci identified in the latest GWAS meta-analyses (Nalls et al., Lancet Neurol 2019; Kim et al., Lancet Neurol 2024).
• Heritability from twin studies is ~30%, comparable to AD; the gap between GWAS-explained and twin-estimated is the “missing heritability”.

The PARK loci were named in chronological order of mapping:

Many original PARK assignments have been reclassified, withdrawn, or merged. The workhorses of modern PD genetics are SNCA, LRRK2, PRKN, PINK1, GBA, and the GWAS signals.

2. SNCA — PARK1/PARK4

The first PD gene cloned. Polymeropoulos et al. (Science 1997) mapped a missense A53T mutation in SNCA in the Italian Contursi kindred and three Greek families with autosomal-dominant PD. Subsequent missense mutations followed: A30P (Krüger 1998), E46K (Zárraga 2004), H50Q (Appel-Cresswell 2013), G51D (Lesage 2013), A53E (Pasanen 2014). All cluster in the N-terminal amphipathic region (residues 1–60).

In 2003 Singleton, Farrer, and Hardy (Science 2003) showed that SNCA gene multiplication — a tandem genomic duplication or triplication of the wild-type locus — causes autosomal-dominant PD by simple gene-dosage effect. Triplication carriers produce ~2× the wild-type protein and develop PD with cognitive decline in their 30–40s; duplication carriers ~1.5× and develop classical PD in their 50–60s. Implication: α-synuclein concentration alone is sufficient to drive disease, validating concentration-lowering as a therapeutic axis (antisense, RNAi, immunotherapy in Part VIII).

Clinical phenotype: SNCA mutations and multiplications produce aggressive PD — earlier onset, faster motor progression, prominent dysautonomia, and dementia in >75%. The pathology shows widespread Lewy pathology often resembling DLB. Penetrance is essentially complete by age 70 for point mutations.

3. LRRK2 — PARK8 — The Most Common Monogenic Cause

LRRK2 (leucine-rich repeat kinase 2) is a 286-kDa multidomain protein encoding a Roc GTPase, COR domain, kinase domain, and protein-interaction domains (ankyrin, LRR, WD40). Identified in 2004 by the Wszolek-Farrer (Neuron 2004) and Paisán-Ruíz/Singleton (Neuron 2004) groups. Mutations are autosomal dominant with reduced age-dependent penetrance (~30% at 80 for G2019S).

The key mutations all cluster in or near the kinase domain and produce kinase gain-of-function:

• G2019S — in the kinase activation loop; ~2–3× baseline kinase activity. Frequency ~1% of all PD; ~5–15% of familial PD; ~30% of Ashkenazi Jewish PD; ~40% of North-African Berber PD — striking founder effect.
• R1441C/G/H — in the Roc domain; impairs GTPase activity, increasing kinase output.
• I2020T — rarer kinase-domain mutation.

LRRK2 phosphorylates a panel of Rab GTPases(Rab8a, Rab10, Rab12, Rab29) at a conserved switch-II threonine (Steger et al., eLife 2016). Hyperphosphorylation of pRab10 disrupts ciliogenesis, lysosomal traffic, and endolysosomal function — converging on the same lysosomal axis as GBA. Pathologically, LRRK2-PD shows variable Lewy-body burden: many G2019S brains have classical Lewy pathology, but a meaningful fraction have pure nigral degeneration without inclusions, raising the possibility that LRRK2 acts upstream of synuclein aggregation rather than always producing it.

Clinical phenotype of LRRK2-PD: clinically indistinguishable from sporadic PD on average, but with a few tendencies — somewhat more benign course, more tremor-dominant, less hyposmia and less RBD, and somewhat lower rate of dementia. The relative paucity of premotor symptoms is a feature that may reflect a different upstream biology and matters for the design of pre-symptomatic prevention trials in carriers.

4. PRKN (Parkin) — PARK2 — The Mitophagy Gene

Identified in Japanese families with autosomal-recessive juvenile-onset PD by Kitada and Mizuno (Nature 1998). Parkin is a 465-residue RBR-class E3 ubiquitin ligase with an N-terminal Ubl domain (binds proteasome) and three RING domains. Loss-of-function mutations — copy-number deletions, point mutations, splice variants — are spread across the gene and account for ~50% of autosomal-recessive early-onset PD(onset <40 yr) and ~15% of sporadic juvenile cases.

Parkin is the executive arm of PINK1-Parkin mitophagy: when mitochondria depolarise, PINK1 (a Ser/Thr kinase) is stabilised on the outer mitochondrial membrane (OMM), recruits and phosphorylates ubiquitin and parkin, activating parkin’s ligase activity. Parkin then ubiquitinates dozens of OMM substrates (Mfn1/2, MIRO, VDAC, TOM20), tagging the damaged mitochondrion for engulfment by autophagosomes (Narendra et al., J Cell Biol 2008; Lazarou et al., Nature 2015). Loss of parkin therefore fails to clear damaged mitochondria — mitochondrial quality control collapses over decades in the most metabolically demanding neurons (the SNc, see Part II).

Clinical phenotype: young-onset(mean ~30 yr; some <20 yr), slowly progressive, exquisitely levodopa-responsive, prone to early dyskinesias, often with dystonia and asymmetric onset. Cognition is typically preserved. Pathologically, parkin-PD often shows nigral neuron loss without Lewy bodies — a striking dissociation that suggests the synuclein aggregation pathway is not strictly required for SNc degeneration, and that parkin sits upstream of (or in parallel with) it.

5. PINK1 and DJ-1 — PARK6 & PARK7

PINK1 (PTEN-induced kinase 1; Valente et al., Science 2004) encodes a 581-residue Ser/Thr kinase with an N-terminal mitochondrial-targeting sequence. In healthy mitochondria PINK1 is constitutively imported into the inner membrane, cleaved by PARL, and degraded by the ubiquitin-proteasome (the “import-degrade” cycle). On membrane- potential collapse, import fails, full-length PINK1 accumulates on the OMM, and it phosphorylates ubiquitin at Ser-65 and parkin at Ser-65 of its Ubl domain — switching parkin from auto-inhibited to active. PINK1 loss therefore phenocopies parkin loss: failed mitophagy, AR juvenile-onset PD, levodopa-responsive, relatively benign.

DJ-1 / PARK7 (Bonifati et al., Science 2003) encodes a 189-residue redox-sensor protein with an active-site Cys-106 that responds to oxidative stress. Functions include glyoxalase activity (detoxifying reactive aldehydes), chaperoning α-synuclein, and modulating mitochondrial complex I. AR LOF mutations cause early-onset PD with ~1–2% of recessive cases. Mechanism remains the murkiest of the three recessive genes; modern attention has focused on its role as an α-synuclein chaperone via DJ-1–Hsp70 interactions.

Together, PRKN, PINK1 and DJ-1 establish mitophagy and oxidative-stress defenceas a recurring axis of PD pathogenesis — aligning with the biochemical picture from MPTP, complex-I deficiency, and SNc-specific Cav1.3-driven calcium load.

6. GBA — The Single Most Important Risk Factor

GBA1 on 1q21 encodes glucocerebrosidase (GCase), the lysosomal enzyme that hydrolyses glucosylceramide to ceramide and glucose. Biallelic loss-of-function causes Gaucher disease, the commonest lysosomal storage disease. The PD link emerged when neurologists noted parkinsonism among Gaucher patients and obligate carriers (Goker-Alpan, Sidransky et al., NEJM 2009). Today GBA heterozygosity is the most prevalent strong risk factor for PD:

• Carrier frequency: ~5% in general European populations; ~15% in Ashkenazi Jews.
• Odds ratio for PD: ~5 overall; mild variants (E326K, T369M) ~1.5–2; severe variants (L444P, 84GG) ~10.
• Lifetime PD risk in heterozygotes: ~10–30% by age 80.
• ~5–15% of all PD patients carry a GBA variant.

Mechanism: reduced GCase activity in lysosomes leads to glucosylceramide accumulation, which stabilises α-synuclein oligomers and impairs lysosomal degradation of synuclein (Mazzulli et al., Cell 2011). A vicious cycle ensues: aggregated synuclein further impairs GCase trafficking, and so on. GCase is therefore both a cause and consequence of synuclein dyshomeostasis — the glucocerebrosidase–α-synuclein axis.

Clinical phenotype of GBA-PD: clinically resembles sporadic PD but with earlier onset (~5 years younger), faster motor progression, more dementia (~2× risk of PDD), more REM-sleep behaviour disorder, and substantially shorter time to dementia. GBA carriers form a high-risk cohort for the disease-modifying trials covered in Part VIII: ambroxol (a chemical chaperone of GCase, MOVES-PD), venglustat (a glucosylceramide synthase inhibitor that backs up GCase failure, MOVES-PD), and AAV-GBA gene therapy.

7. Other Mendelian Genes

• VPS35 (PARK17) — D620N is the only proven pathogenic mutation. VPS35 is a retromer component that recycles cargo from endosomes to the trans-Golgi or plasma membrane. AD inheritance with reduced penetrance; phenotype resembles classical PD. Mechanism intersects LRRK2 (Rab10), retromer-dependent traffic of LAMP2A (the receptor for chaperone-mediated autophagy), and lysosomal stability.
• ATP13A2 / PARK9 — Kufor-Rakeb syndrome: AR juvenile-onset parkinsonism + dementia + supranuclear gaze palsy + pyramidal signs. Lysosomal P5-type cation transporter, polyamine homeostasis. Rare. Reinforces the lysosomal axis.
• PLA2G6 / PARK14 — phospholipase A2; AR; juvenile-onset parkinsonism + dystonia, brain iron accumulation.
• FBXO7 / PARK15 — F-box protein; AR; rare juvenile-onset.
• DNAJC6 / PARK19, SYNJ1 / PARK20 — synaptic-vesicle endocytosis genes; AR juvenile-onset atypical parkinsonism.
• MAPT (H1 haplotype) — tau gene; risk modifier for sporadic PD; the H1 haplotype increases risk ~1.5×. Same gene as PSP/CBD.
• CHCHD2, TMEM230 — rare AD families; mitochondrial intermembrane-space proteins.

The aggregate picture: PD genes converge on three pathways: (1) α-synuclein homeostasis (SNCA, GBA), (2) mitochondrial quality control (PRKN, PINK1, DJ-1, CHCHD2), and (3) lysosomal/endolysosomal traffic (LRRK2, GBA, VPS35, ATP13A2). Many genes participate in multiple axes simultaneously — LRRK2 phosphorylates Rabs (lysosome) and modulates mitophagy; GBA reduces lysosomal capacity and destabilises synuclein. The unified failure mode is proteostatic collapse in a metabolically stressed dopamine neuron.

8. GWAS and Polygenic Risk

The 2019 Nalls et al. meta-GWAS (Lancet Neurol 2019) brought ~37,000 cases and ~1.4 million controls together and identified 90 independent risk loci (since extended to ~120 in 2024 by the IPDGC and 23andMe collaborations). Several important findings:

• The strongest GWAS signals overlap the Mendelian genes: SNCA, LRRK2, GBA, MAPT, VPS13C.
• Polygenic risk score (PRS) accounts for ~16–22% of disease liability; combined with GBA + LRRK2 status, ~25–30%.
• Pathway enrichment highlights lysosomal function, autophagy, mitochondrial homeostasis, and inflammation.
• Drug-target prioritisation (Mendelian randomisation) has flagged GBA agonism, LRRK2 inhibition, and acid sphingomyelinase modulation.

GWAS-derived PRS is now used to enrich prevention-trial cohorts (combined with prodromal markers), to risk-stratify carriers of LRRK2/GBA variants, and to probe causal architecture via Mendelian randomisation (e.g., showing that elevated LDL is a probable causal risk factor for PD; smoking inversely so).

9. Genetic Testing in Practice

The MDS Genetics Task Force (Cook et al., Mov Disord 2021) recommends genetic testing in the following clinical contexts:

• Early-onset PD (<50 yr) — PRKN, PINK1, DJ-1 (recessive panel) plus GBA and LRRK2 (dominant).
• Juvenile-onset (<21 yr) — expand to ATP13A2, PLA2G6, FBXO7, DNAJC6, SYNJ1.
• Family history of PD — LRRK2 (especially in Ashkenazi/Berber/Basque), SNCA (point + dosage), GBA.
• Atypical features (cognitive decline, autonomic prominence) — SNCA dosage; consider DLB/MSA differential.
• Eligibility for clinical trials — GBA and LRRK2 status increasingly required for stratified disease-modifying studies.

Open-access genotyping initiatives such as PD GENEration(Parkinson’s Foundation) and the Global Parkinson’s Genetics Program (GP2) now offer free testing of LRRK2/GBA/SNCA panels to tens of thousands of patients globally. The aim is twofold: clinically, to enable targeted-therapy trial enrolment; scientifically, to uncover the genetic architecture in under-studied populations.

The clinical implications of these genetic insights are operationalised in Part VI (Diagnosis) and Part VIII (Future Directions), where the next generation of LRRK2-, GBA-, and SNCA-targeted therapies is reviewed.